LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

CareDx Inc

Cerrado

SectorSalud

19.32 2.33

Resumen

Variación precio

24h

Actual

Mínimo

18.9

Máximo

19.33

Métricas clave

By Trading Economics

Ingresos

85M

78M

Ventas

3.7M

87M

P/B

Media del Sector

20.72

71.874

BPA

0.18

Margen de beneficio

90.103

Empleados

644

EBITDA

90M

84M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+44.05% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-78M

1.1B

Apertura anterior

16.99

Cierre anterior

19.32

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

325 / 387 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 mar 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Global Business Travel Group Cuts Price of Deal for Rival CWT

22 mar 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

22 mar 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 mar 2025, 01:00 UTC

Adquisiciones, fusiones, absorciones

The $32 Billion Wizards Who Picked the Best Time to Start a Company: The Worst Time -- WSJ

21 mar 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Ranking the S&P 500s Most Defensive Stocks -- Barrons.com

21 mar 2025, 22:15 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms: Unit Will Provide $185M to Rhodium on Deal Close >RIOT

21 mar 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms: Motion Filed to Approve Settlement in Rhodium's Bankruptcy Case

21 mar 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

Riot Platforms Enters Non-Binding Term Sheet to Buy Certain Assets of Rhodium Encore >RIOT

21 mar 2025, 22:03 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- 4th Update

21 mar 2025, 21:05 UTC

Principales Noticias

The Score: Nvidia, Tesla, Nike and More Stocks That Defined the Week -- WSJ

21 mar 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

21 mar 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 mar 2025, 20:24 UTC

Principales Noticias

Major Indexes Stage Late Rally -- WSJ

21 mar 2025, 20:01 UTC

Principales Noticias

Columbia Yields to Trump in Battle Over Federal Funding -- WSJ

21 mar 2025, 19:40 UTC

Charlas de Mercado

Walmart's Beauty Marketplace Push Puts Ulta Beauty at Risk -- Market Talk

21 mar 2025, 19:29 UTC

Charlas de Mercado

Oil Futures Post Moderate Weekly Gains -- Market Talk

21 mar 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Grapple With $4 Level -- Market Talk

21 mar 2025, 19:02 UTC

Charlas de Mercado

Gold Eases to End Record-Setting Week -- Market Talk

21 mar 2025, 18:52 UTC

Charlas de Mercado

Telus Downgraded on Leverage, Cash Flow, Dividend Concerns -- Market Talk

21 mar 2025, 18:49 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- Third Update

21 mar 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Aggressive Discounting Of Classics Could Damage Brand -- Market Talk

21 mar 2025, 18:07 UTC

Principales Noticias

Major Indexes Swing Around the Flatline -- WSJ

21 mar 2025, 18:07 UTC

Charlas de Mercado
Ganancias

Nike's Focus On Hot New Products May Not Offset Decline In Classic Styles -- Market Talk

21 mar 2025, 17:41 UTC

Charlas de Mercado
Ganancias

Nike's Turnaround Messaging May Add Some Confusion -- Market Talk

21 mar 2025, 17:41 UTC

Principales Noticias

Trump to Announce Multibillion-Dollar Jet Fighter -- Second Update

21 mar 2025, 17:41 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

21 mar 2025, 17:17 UTC

Charlas de Mercado

U.S. Oil Rig Count Slips By One to 486 -- Market Talk

21 mar 2025, 17:06 UTC

Charlas de Mercado

Bitcoin Treads Water After Trump Address -- Market Talk

21 mar 2025, 16:54 UTC

Charlas de Mercado
Ganancias

FedEx Assumed an Industrial Ramp Up That Didn't Come -- Market Talk

21 mar 2025, 16:40 UTC

Charlas de Mercado

Mexican Inflation Likely Slowed in Early March -- Market Talk

Comparación entre iguales

Cambio de precio

CareDx Inc Esperado

Precio Objetivo

By TipRanks

44.05% repunte

Estimación a 12 meses

Media 27.83 USD  44.05%

Máximo 35 USD

Mínimo 23.5 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

18.965 / 19.6Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

325 / 387 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.